Sandoz AG and its group companies have reached final agreements with Strides Pharma Science Limited's step-down subsidiary, Strides Pharma International AG (SPIAG), for the purchase and in-licensing of a portfolio of branded generic products throughout Sub-Saharan Africa (SSA).

 

The deal covers Ghana, Nigeria, Kenya and Western Sahara, which includes ten countries. The portfolio comprises branded generics in the dermatological, cardiovascular, and anti-infective categories; several of these drugs alone bring in more than $1 million annually.

 

A variety of items are being fully bought by Strides as part of the deal, along with a few that Strides will keep marketing on Sandoz's behalf. In order to maintain production and supply, Strides and Sandoz will enter into a manufacturing and supply agreement.

 

Strides is anticipated to rank in the top two in the representable market and among the top five pharmaceutical companies in the SSA area by sales with the combined portfolio. Additionally, it is anticipated that the deal will more than double Strides' local footprint.

 

US$12 million is the transaction's initial consideration, which will be paid at close and is anticipated to be financed by internal accruals. It is anticipated that the deal will be EPS-accretive.Subject to regulatory and antitrust approvals, the deal is anticipated to completion by the end of Q2 FY27 (quarter ending September 2026).